Patheon — Q2 2012 Earnings Presentation
16 slides from Patheon's earnings presentation, Jun 13, 2012
Slide 1: Fiscal 2012 Second Quarter Earnings
Patheon Fiscal 2012 Second Quarter Earnings June 13, 2012 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements or information which reflect our expectations regarding possible events, conditions, our future growth, results of operations, performance, and business prospects and opportunities. All statements, other than statements
Slide 3: Agenda
Agenda • Highlights • Financial results • Transformation update • Conclusion
Slide 4: Second Quarter Highlights
Second Quarter Highlights 18.9% revenue growth* Significant increase in gross profit* * Excluding the $17.4M benefit from the contract cancellation reco rded in the second quarter of fiscal 2011 Raising revenue guidance - in excess of $725M Transformation on track
Slide 5: Revenue Overview
Revenue Overview Q2 2011 Q3 2011 Q4 2011 Q1 2012 Q2 2012 18.9% yr-yr revenue growth excluding the benefit from contract cancellation Revenue (U.S. $ in millions) Adjusted Revenue (U.S. $ in millions) Q2 2011 Q3 2011 Q4 2011 Q1 2012 Q2 2012
Slide 6: Gross Profit Overview
Gross Profit Overview Q2 2011 Q3 2011 Q4 2011 Q1 2012 Q2 2012 Gross Profit (U.S. $ in millions) Q2 2011 Q3 2011 Q4 2011 Q1 2012 Q2 2012 Gross profit growth from $13M to $34M excluding the benefit from contract cancellation Adjusted Gross Profit (U.S. $ in millions)
Slide 7: Adjusted EBITDA Overview
Adjusted EBITDA Overview -15 -5 Q2 2011 Q3 2011 Q4 2011 Q1 2012 Q2 2012 Adjusted EBITDA (U.S. $ in millions) Adjusted EBITDA Excluding Certain Items (U.S. $ in millions) -15 -5 Q2 2011 Q3 2011 Q4 2011 Q1 2012 Q2 2012
Slide 8: Summary Financial Results
Summary Financial Results Three months ended April 30, Statement of Operations (in millions of U.S. dollars) $ $ Revenues 181.5 170.0 Gross profit 34.0 30.4 Selling, general and administrative expenses 34.7 24.8 Operating (loss) income (64.6) 4.7 Loss before discontinued operations (79.6) (10.3) Adj
Slide 9: Strategy
Strengthen core operations Sell business differently Enter logical adjacencies Drive industry consolidation Strategy
Slide 10: Strengthen core operations
Strengthen core operations Mindsets & Behaviors Infrastructure Leveraging global network Swindon announcement Clinical packaging Puerto Rico consolidation on track Improving resource coordination Lab design and work flow Expanding operational capacity Italy pre-filled syringe line G&A and procuremen
Slide 11: Sell business differently
Sell business differently Value-drive solutions for our customers: Expanded CMC and Scientific Consulting offerings to position the brand differently: Patheon Certified Consultants
Slide 12: Launched P-Gels in May: Enter logical adjacencies
Launched P-Gels in May Enter logical adjacencies Leverages expertise of both companies Patheon – sales and marketing reach and largest development pipeline ProCaps – softgel related technology, formulation and manufacturing expertise, and infrastructure
Slide 13: Summary
Summary • Underlying business is strong with growing revenues and improving margins • Transformation activities are on track • Balance sheet and liquidity are good • Raising top-line guidance
Slide 14: Thank You
Thank You
Slide 15: Appendix: Adjusted Revenue and Gross Profit
Appendix Adjusted Revenue (unaudited) Q211 Q311 Q411 Q112 Q212 (in millions of U.S. dollars) $ $ $ $ $ Revenues 170.0 172.7 181.6 153.9 181.5 Contract cancellation (17.4) - - - - Adjusted Revenue 152.6 172.7 181.6 153.9 181.5 Adjusted Gross Profit (unaudited) Q211 Q311 Q411 Q112 Q212 (in millions of
Slide 16: Appendix: Adjusted EBITDA Reconciliation
Appendix Adjusted EBITDA and Adjusted EBITDA Excluding Certain Items (unaudited) Q2 2011 Q3 2011 Q4 2011 Q1 2012 Q2 2012 (in millions of U.S. dollars) $ $ $ $ $ Loss before discontinued operations (10.3) 0.6 (9.8) (19.3) (79.6) Depreciation and amortization 13.5 12.6 12.2 10.6 10.8 Repositioning exp